C4 Therapeutics (CCCC) PT Lowered to $22 at UBS
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $4.00 --0%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 23
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 23
Join SI Premium – FREE
UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $22.00 (from $24.00) while maintaining a Buy rating.
You May Also Be Interested In
- Barclays Downgrades Unite Group (UTG:LN) to Underweight
- TPG Telecom Limited (TPG:AU) (TPGTF) PT Raised to AUD4.10 at UBS
- Barclays Downgrades Shurgard Self Storage SA (SHUR:BB) to Underweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
